SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Universe Pharmaceuticals INC (UPC) (CIK 0001809616) (UPC) — Mar 17, 2021

Universe Pharmaceuticals INC (UPC) (CIK 0001809616)
Date: March 17, 2021 · CIK: 0001809616 · Accession: 0001213900-21-016140

AI Filing Summary & Sentiment

File numbers found in text: 333-248067

Date
March 17, 2021
Author
LLC
Form
CORRESP
Company
Universe Pharmaceuticals INC (UPC) (CIK 0001809616)

Letter

March 17, 2021

Via Edgar

Mr. Alan Campbell

Division of Corporation Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, D.C., 20549

Re: Universe Pharmaceuticals INC

Registration Statement on Form F-1/A (File No. 333-248067)

Request for Acceleration of Effectiveness

Ladies and Gentlemen:

In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), Univest Securities, LLC, as the underwriter, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on March 22, 2021, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

We are aware of our obligations under and confirm that they are complying with the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, including the delivery requirement contained in such Rule.

Very truly yours,
Univest Securities,
LLC

Show Raw Text
CORRESP
1
filename1.htm

March 17, 2021

Via Edgar

Mr. Alan Campbell

Division of Corporation Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

100 F Street, NE

Washington, D.C., 20549

    Re:
    Universe Pharmaceuticals INC

        Registration Statement on Form F-1/A (File No. 333-248067)

        Request for Acceleration of Effectiveness

Ladies and Gentlemen:

In accordance with Rule
461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), Univest
Securities, LLC, as the underwriter, hereby requests acceleration of the effective date of the above-referenced Registration Statement
so that it will become effective at 4:00 p.m., Eastern Time, on March 22, 2021, or as soon thereafter as practicable.

Pursuant to Rule 460 under
the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated to be invited
to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to
be reasonable to secure adequate distribution of the preliminary prospectus.

We are aware of our obligations
under and confirm that they are complying with the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended,
including the delivery requirement contained in such Rule.

Very truly yours,

Univest Securities,
LLC

By: /s/ Edric Guo

Name:	Edric Guo

Title:	Chief Operating Officer